ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Calidi Biotherapeutics, Inc. (CLDI) shows an Average True Range (ATR) of 0.15 and an Enterprise Value of N/A. Its average trading volume over the past 3 months is 17.11M, indicating liquidity. These fundamental metrics provide insight into CLDI's underlying financial health and market activity.
Calidi Biotherapeutics, Inc. (CLDI) technical indicators as of July 31, 2025: the SMA 20 is -1.85%, SMA 50 at 33.6%, and SMA 200 at -37.36%. The RSI 14 value is 51.59, suggesting its current momentum. These technical analysis signals help assess CLDI's price trends and potential future movements.
Calidi Biotherapeutics, Inc. (CLDI) stock performance overview as of July 31, 2025: The 52-week high is $3.89 (currently -84.96% below), and the 52-week low is $0.203 (currently 188.65% above). Over the past year, CLDI's performance is -65.58%, compared to the S&P 500's 17.04% change.
According to market data, Calidi Biotherapeutics, Inc. (CLDI) stock's recent performance metrics show that over the last month, CLDI is 154.39%, with a Year-to-Date (YTD) performance of -49.12%. Over the past year, the stock has seen a -65.58% change. These figures summarize CLDI's price movements across various periods, reflecting its historical returns.
According to current financial data, CLDI stock's P/E (TTM) ratio is -0.73, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for CLDI, including P/S (N/A), P/B (2.27), and P/FCF (-2.21), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.